Andere Sprachen Arcellx, Inc.

Aktien

A3DEJC

US03940C1009

ACLX

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:46:58 03.05.2024			% 5 Tage	% 1. Jan.
53,96 ^USD	+1,26 %		+4,95 %	-1,82 %

18.04.	Arcellx-Insider verkauft Aktien im Wert von $522.260, laut einer aktuellen SEC-Einreichung	MT
03.04.	Arcellx-Insider verkauft Aktien im Wert von $1.548.887, laut einer aktuellen SEC-Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Arcellx Insider Sold Shares Worth $522,260, According to a Recent SEC Filing	18.04.
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference	04.04.
Arcellx Insider Sold Shares Worth $1,548,887, According to a Recent SEC Filing	03.04.
Arcellx Insider Sold Shares Worth $35,575,755, According to a Recent SEC Filing	25.03.
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	20.03.
Arcellx Insider Sold Shares Worth $633,582, According to a Recent SEC Filing	19.03.
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference	29.02.
Arcellx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.
Earnings Flash (ACLX) ARCELLX Posts Q4 Revenue $63.1M	28.02.
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights	28.02.
Arcellx, Inc. Enters an Assignment of Lease with A Third Party Sublessee	31.01.
Arcellx, Inc. Approves Relocation of the Headquarters	31.01.
Arcellx Insider Sold Shares Worth $419,926, According to a Recent SEC Filing	08.01.
Arcellx Insider Sold Shares Worth $1,606,804, According to a Recent SEC Filing	08.01.
Arcellx Insider Sold Shares Worth $470,551, According to a Recent SEC Filing	08.01.
Arcellx Insider Sold Shares Worth $6,020,281, According to a Recent SEC Filing	19.12.
Arcellx Insider Sold Shares Worth $24,774,441, According to a Recent SEC Filing	18.12.
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH	11.12.
Arcellx Phase 1 Expansion Study Data for Cancer Candidate Shows 100% Overall Response Rate	08.12.
Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash	08.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Arcellx, Inc.

Aktien

A3DEJC

US03940C1009

ACLX

Andere Sprachen

Filter